Key Takeaways:
NervGen Pharma Corp. (NASDAQ: NGEN) priced an underwritten public offering of 24 million common shares at $2.50 per share, aiming to raise approximately $60 million in gross proceeds.
The clinical-stage biopharmaceutical company announced the pricing late Wednesday, with the securities offered in all provinces and territories of Canada, other than Quebec. The company intends to use the net proceeds, along with existing cash, to advance its lead therapeutic candidate, NVG-291, through clinical studies and for general corporate purposes, according to a statement.
The offering price of $2.50 represents a 32 percent discount to the stock's closing price of $3.68 on May 21. Each common share is accompanied by a warrant to purchase one common share at an exercise price of $3.68. The warrants are immediately exercisable and will expire five years from the date of issuance. The offering is expected to close on or about May 26, 2026, subject to customary closing conditions.
The capital raise and its dilutive terms put significant pressure on the company's stock, which fell nearly 15 percent in after-hours trading to $3.13 following the announcement. The deal structure means an immediate increase of 24 million shares, with the potential for another 24 million to be issued if the warrants are exercised, a substantial dilution for existing shareholders.
NervGen is focused on developing treatments for spinal cord injury and other neurological conditions. Its lead candidate, NVG-291, has received Fast Track designation from the U.S. Food and Drug Administration. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.
The financing provides NervGen with a crucial cash runway to advance its expensive, late-stage clinical trials for NVG-291. Investors will now be focused on the company's execution of these trials and its management of cash burn ahead of key data readouts.
This article is for informational purposes only and does not constitute investment advice.
